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Spaces (STAS) is Prognostic
in Atypical Carcinoid, Large
Cell Neuroendocrine
Carcinoma, and Small Cell
Carcinoma of the LungTo the Editor:
Since the concept of “spread through air spaces”
(STAS) was included in the 2015 WHO book on clas-
sification of lung cancer, the manuscript by Aly et al.,1
is the first study proposing detailed histologic criteria
to distinguish STAS from other forms of “loose tumor
fragments”: tumor floaters and artifacts1 in lung
neuroendocrine neoplasms. These expert opinion
criteria are not supported by evidence showing
prognostic differences in cases that exhibit STAS
versus loose tumor fragments. In addition, the
proposed criteria rely mostly on the detection of
loose tumor fragments with smooth edges in spatial
continuity with the tumor and within a certain
distance to the lesion. Loose tumor fragments with
jagged or ragged margins and/or those located far
away from the tumor (“more than four airspacesaway,” as shown in Fig. 2) or at the edge of a tissue
section are designated as an artifact.2 The proposed
criteria depend on an arbitrary distance between the
tumor and the loose fragments, and the ability of
pathologists to distinguish smooth from jagged or
ragged edges. The difficulty of interpreting the
characteristics of tumor borders is underscored by
looking at the examples of STAS provided in
Figure 1, taken at 100. In our opinion, it is difficult
at this magnification to evaluate whether the
fragments have round or jagged/ragged edges. The
proposed criteria also raise questions as to why a
tumor would always spread only through fragments
with smooth borders. Indeed, previous studies have
shown that the knife can disseminate tumor
fragments with smooth or ragged margins radially
from tumor edges into holes in tissue or into the
edge of tissue sections.
A previous study of the presence of STAS on frozen
section did not find sufficient evidence to support the
routine reporting of STAS during intraoperative con-
sultations.2 To our knowledge, there are no clinical
trials supporting the use of STAS as a predictive
feature. Previous studies have used variable
definitions for the identification of STAS on tissue
sections, precluding the use of meta-analysis to
aggregate available evidence about the association
between STAS and prognosis.2 Moreover, in the article
by Aly et al.,1 at least 88% (43 out of 49) of the
STAS in typical carcinoids is present in cases
without recurrence or lung cancer–specific death.
Recent reports3,4 (and references herein) have
described as artifacts the presence of loose
fragments in different neoplastic and non-neoplastic
lesions such as in diffuse idiopathic pulmonary
neuroendocrine cell hyperplasia.4 Studies performing
July 2020 Letters to the Editor e1173D reconstructions evaluating the continuity between
the main tumor and the detached cells have shown
that the latter represent tentacles of inherently
fragile structures.5
In summary, the diagnostic criteria for the distinction
between STAS and artifacts proposed by Aly et al.,1 need
to be defined in more detail with studies showing
diagnostic reproducibility and correlation with
prognosis and prediction before the controversy as to
whether pathologists can distinguish the so-called STAS
from artifacts is put to rest.
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